Auris Medical Holding Ltd. (EARS) stock announced positive results of its in vivo study of OligoPhoreTM technology in adults after which the EARS stock price saw an uptrend of 9.04% to reach $3.62 a share at the time of this writing. It seems that momentum was already built in the previous session as EARS went up by 0.61% at closing. Let’s deeply discuss the EARS stock.
OligoPhoreTM siRNA Study:
Investors are responding positively to the announcement by EARS stock on June 21, 2021, according to which EARS’ OligoPhoreTM siRNA targeting the NF-κBinAdult T-cell Leukemia Lymphoma (ATLL) has significantly refrained the tumor growth. The research groups jointly conducted the study at the University of South Florida, Tampa FL, and the Washington University, St. Louis MO. The RNA nanoparticles were developed and evaluated by researchers of the study. In this process, two NF-κB signaling pathways were targeted by siRNA and peptide carrier of Auris’s OligoPhoreTM. The research groups administered siRNA nanoparticles to two mice groups with either tumor cell transplantation or ATLL tumor growth.
Study Results:
The study showed positive results as siRNA delivered rapidly to the tumor and target mRNA and protein expression had been significantly reduced which resulted the inhibit tumor growth. Tumor size, spleen size and peripheral blood lymphocyte counts were reduced significantly in the mice participated in the study as compared to control and the most aggressive tumors showed nearly zero growth.
Acquisition of Trasir Therapeutics, Inc:
On June 03, 2021, Auris stock entered the field of RNA therapeutics via the acquisition of Trasir Therapeutics, Inc , which is a private company in Tampa, FL famous for extrahepatic oligonucleotide delivery. The purchase price for this acquisition was $0.77 million common shares of EARS stock. The transaction was closed on June 1, 2021. The Trasir’s founder, Dr. Samuel Wickline joined the EARS’ leadership team by taking the role of Chief Scientific Officer.
Repositioning of EARS stock:
The Auris Medical initiated its repositioning via the acquisition of Trasir Therapeutics and aims to develop RNA therapeutics in the future amid spinning off existing assets in neurotology, rhinology, and allergology. EARS board of directors proposed a change in corporate name to Altamira Therapeutics Ltd in order to reflect the strategic repositioning. The shares will start to trade under the ticker symbol CYTO upon regulatory approvals.
Conclusion:
So far so good for Auris Medical stock as far as market sentiment is concerned due to the release of positive in vivo results of OligoPhoreTM siRNA Study by EARS stock. The management is focused in the repositioning of the company and planning to grow via the development of RNA therapeutics. In a nutshell, this stock can prove to be fruitful in the long run.
